Harpoon Therapeutics Abstract for HPN328 Accepted for Rapid Oral Presentation at the 2024 American Society of Clinical Oncology Genitourinary Cancers Symposium
19 déc. 2023 07h30 HE
|
Harpoon Therapeutics Inc.
SOUTH SAN FRANCISCO, Calif., Dec. 19, 2023 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (Nasdaq: HARP), a clinical-stage immunotherapy company developing novel T cell engagers, today announced...